Drug Dosing during Intermittent Hemodialysis and Continuous Renal Replacement Therapy: Special Considerations in Pediatric Patients

被引：20

作者：

Veltri M.A. ^{[1
,4
]}

Neu A.M. ^{[2
]}

Fivush B.A. ^{[2
]}

Parekh R.S. ^{[2
]}

Furth S.L. ^{[2
,3
]}

机构：

[1] Pediatric Division, Department of Pharmacy, Johns Hopkins Medical Institutions, Baltimore, MD

[2] Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, MD

[3] W. Ctr. Prev., Epidemiol./Clin. Res., Johns Hopkins Medical Institutions, Baltimore, MD

[4] Department of Pharmacy, Johns Hopkins Hospital, Carnegie 180, Baltimore, MD 21287-6180

来源：

Pediatric Drugs | 2004年 / 6卷 / 1期

关键词：

Continuous Renal Replacement Therapy; Clavulanic Acid; Blood Flow Rate; Residual Renal Function; Dialysate Flow;

D O I：

10.2165/00148581-200406010-00004

中图分类号：

学科分类号：

摘要：

Chronic renal failure is, fortunately, an unusual occurrence in children; however, many children with various underlying illnesses develop acute renal failure, and transiently require renal replacement therapy - peritoneal dialysis, intermittent hemodialysis (IHD), or continuous renal replacement therapy (CRRT). As children with acute and chronic renal failure often have multiple comorbid conditions requiring drug therapy, generalists, intensivists, nephrologists, and pharmacists need to be aware of the issues surrounding the management of drug therapy in pediatric patients undergoing renal replacement therapy. This article summarizes the pharmacokinetics and dosing of many drugs commonly prescribed for pediatric patients, and focuses on the management of drug therapy in pediatric patients undergoing IHD and CRRT in the intensive care unit setting. Peritoneal dialysis is not considered in this review. Finally, a summary table with recommended initial dosages for drugs commonly encountered in pediatric patients requiring IHD or CRRT is presented.

引用

页码：45 / 65

页数：20

共 113 条

[1]

Colton C.K., Henderson L.W., Ford C.A., Et al., Kinetics of hemodiafiltration (I): In vitro transport characteristics of a hollow-fiber blood ultrafilter, J Lab Clin Med, 85, 3, pp. 355-371, (1975)

[2]

Golper T.A., Pullium J., Bennett W.M., Removal of therapeutic drugs by continuous arteriovenous hemofiltration, Arch Intern Med, 145, pp. 1651-1652, (1985)

[3]

Golper T.A., Wedel S.K., Kaplan A.A., Et al., Drug removal during continuous arteriovenous hemofiltration: Theory and clinical observations, Int J Artif Organs, 8, pp. 307-312, (1985)

[4]

Levin D.L., Morriss F.C., Essentials of Pediatric Intensive Care: Pharmacokinetics in Patients on Extracorporeal Circuits. 2nd Ed., (1997)

[5]

Joy M.S., Matzke G.R., Armstrong D.K., Et al., A primer on continuous renal replacement therapy for critically ill patients, Ann Pharmacother, 32, 3, pp. 362-375, (1998)

[6]

Reetze-Bonorden P., Bohler J., Keller E., Drug dosage in patients during continuous renal replacement therapy: Pharmacokinetic and therapeutic considerations, Clin Pharmacokinet, 24, 5, pp. 362-379, (1993)

[7]

Golper T.A., Drug removal during continuous hemofiltration or hemodialysis, Contrib Nephrol, 93, pp. 110-116, (1991)

[8]

Davies J.G., Kingswood J.C., Sharpstone R., Et al., Drug removal in continuous haemofiltration and haemodialysis, Br J Hosp Med, 54, 10, pp. 524-528, (1995)

[9]

Manns M., Sigler M.H., Teehan B.P., Continuous renal replacement therapies: An update, Am J Kidney Dis, 32, 2, pp. 185-207, (1998)

[10]

Bohler J.D.J., Keller F., Pharmacokinetic principles during continuous renal replacement therapy: Drugs and dosage, Kidney Int Suppl, 72, (1999)

← 1 2 3 4 5 6 7 8 9 10 →